| Literature DB >> 26203256 |
Frank Noack1, Bernd Schmidt2, Mroawan Amoury3, Dietrich Stoevesandt4, Stephan Gielen5, Birgit Pflaumbaum6, Christiane Girschick6, Heinz Völler7, Axel Schlitt8.
Abstract
BACKGROUND: Venous thromboembolism is a life-threatening disease. In survivors, different degrees of functional complaints need to be restored or prevented (eg, post-thrombotic syndrome, pulmonary hypertension). Therefore, rehabilitation after venous thromboembolism is recommended in Germany. However, a structured rehabilitation program has not been defined for this indication. Here, we present the experience of a single rehabilitation center.Entities:
Keywords: pulmonary embolism; rehabilitation; venous thromboembolism
Mesh:
Substances:
Year: 2015 PMID: 26203256 PMCID: PMC4508081 DOI: 10.2147/VHRM.S81411
Source DB: PubMed Journal: Vasc Health Risk Manag ISSN: 1176-6344
Patient characteristics
| Variable | n=422 |
|---|---|
| Sociodemographic data | |
| Age (years) | 63.9±13.5 |
| Female sex (%) | 51.9 |
| BMI (kg/m2) | 30.6±6.2 |
| Patient history | |
| Deep vein thrombosis related to PE (%) | 55.5 |
| Active smoking (%) | 6.2 |
| Hypertension (%) | 72.7 |
| Diabetes (%) | 22.7 |
| COPD (%) | 13.0 |
| Renal insufficiency | 7.3 |
| Atrial fibrillation (%) | 9.7 |
| Coronary heart disease (%) | 9.5 |
| Vital parameters | |
| BP systolic (mmHg)* | 135.3±19.1 |
| BP diastolic (mmHg)* | 80.7±10.8 |
| Heart rate (bpm)* | 75.4±11.1 |
Notes: Categorical variables are presented in percent; continuous normally distributed variables as mean ± standard deviation *at admission.
Abbreviations: BMI, body mass index; PE, pulmonary embolism; BP, blood pressure; bpm, beats per minute.
Drug treatment at admission and discharge
| Drug | Admission | Discharge |
|---|---|---|
| LMWH (%) | 16.1 | 3.8 |
| Oral anticoagulants | ||
| VKA (%) | 79.4 | 85.8 |
| Rivaroxaban (%) | 9.0 | 10.0 |
| Dabigatran (%) | 0.5 | 0.5 |
| Aspirin (%) | 7.6 | 4.3 |
| Beta-blockers (%) | 51.7 | 59.5 |
| ACE-inhibitors (%) | 35.8 | 37.0 |
| ARBs (%) | 26.1 | 28.9 |
| Statins (%) | 21.8 | 44.1 |
| Insulin (%) | 8.8 | 8.5 |
| Antidiabetics (%) | 8.3 | 8.8 |
| Antidepressives (%) | 7.3 | 7.3 |
Abbreviations: LMWH, low-molecular-weight heparin; VKA, vitamin K antagonist; ACE, angiotensin-converting-enzyme; ARB, angiotensin-receptor blocker.
Figure 1Adverse events.
Therapeutic interventions and adverse events
| Variable | All | No AEs | AEs | |
|---|---|---|---|---|
| Bicycle training with monitored heart rate (%) | 86.7 | 88.2 | 77.2 | 0.220 |
| Medical training therapy (%) | 14.9 | 15.6 | 10.5 | 0.316 |
| Group exercising (%) | 60.7 | 61.4 | 56.1 | 0.452 |
| Chair exercises (%) | 40 | 37.5 | 56.1 | 0.008 |
| Group gymnastics (%) | 11.1 | 12.3 | 3.5 | 0.049 |
| Group aquatic therapy (%) | 28.7 | 29 | 26.3 | 0.672 |
| Pulmonological functional exercise (%) | 14.9 | 15.6 | 10.5 | 0.316 |
| Pulmonological functional exercise as aquatic therapy (%) | 9 | 9.3 | 7 | 0.573 |
| Walking exercise (%) | 8.1 | 6.6 | 17.5 | 0.005 |
| Respiratory therapy/training (%) | 82.5 | 81.9 | 86 | 0.455 |
| Nordic walking (%) | 28 | 30.7 | 10.5 | 0.002 |
| Refective respiratory therapy (%) | 10.4 | 9.3 | 17.5 | 0.059 |
| Swimming (%) | 40.8 | 41.6 | 35.1 | 0.349 |
Abbreviation: AEs, adverse events.